Core Insights - Neumora Therapeutics has initiated a Phase 1b study for NMRA-511, targeting agitation associated with Alzheimer's disease (AD) [11][12] - NMRA-511 is a highly potent and selective antagonist of the vasopressin 1a receptor (V1aR), which is implicated in regulating aggression, stress, and anxiety responses [7][11] - The study aims to evaluate the safety, tolerability, and efficacy of NMRA-511 in both healthy elderly participants and individuals with agitation due to AD [11][12] Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain diseases, with a pipeline of seven clinical and preclinical neuroscience programs [3][11] - The company's mission is to redefine neuroscience drug development by utilizing advanced translational, clinical, and computational tools to enable precision medicine approaches [3] Clinical Study Details - The Phase 1b study consists of two parts: Part A will involve approximately 8 healthy elderly participants, while Part B will include around 88 individuals with agitation associated with dementia due to AD [11] - The primary endpoint of the study is the change from baseline to Week 8 on the Cohen-Mansfield Agitation Inventory total score [11] Market Context - Approximately 7 million people in the U.S. currently live with Alzheimer's disease, with projections indicating this number could exceed 13 million by 2050 [13] - Behavioral symptoms, particularly agitation, affect about 70% of individuals with AD, leading to significant disability and caregiver stress [13] - Currently, there is only one approved treatment for agitation in AD, which carries a black box warning for increased mortality in elderly patients, highlighting a substantial unmet medical need [13]
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation